TITLE

Trastuzumab and cardiotoxicity: Weighing the risks

AUTHOR(S)
Siu-Fun Wong
PUB. DATE
March 2006
SOURCE
American Journal of Health-System Pharmacy;3/15/2006, Vol. 63 Issue 6, p525
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article discusses the risk of cardiotoxicity associated with trastuzumab, a component of various chemotherapy regimens that has been widely accepted by the oncology community as a therapeutic option for women with metastatic breast cancer. Attention is given questions raised by Kabe and Kolesar from their review of published interim analyses of trials of adjuvant trastuzumab in patients with early-stage breast cancer. More studies are needed to determine if the cardiac risk outweighs the benefit in patients with small tumors and node-negative breast cancer.
ACCESSION #
20082525

 

Related Articles

  • External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. Booth, Christopher M.; Dranitsaris, George; Gainford, M. Corona; Berry, Scott; Fralick, Michael; Fralick, John; Sue, Joanna; Clemons, Mark // BMC Cancer;2007, Vol. 7, p110 

    Background: Setting priorities for the funding of new anti-cancer agents is becoming increasingly complex. The funding of adjuvant trastuzumab for breast cancer has brought this dilemma to the fore. In this paper we review external factors that may influence decision-making bodies and present a...

  • Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. Viani, Gustavo A; Afonso, Sergio L.; Stefano, Eduardo J.; De Fendi, Ligia I.; Soares, Francisco V. // BMC Cancer;2007, Vol. 7, p153 

    Background: Breast cancer is the most common cancer in women in the U.S. and Western Europe. Amplification of the her-2/neu gene occurs in approximately 25% of invasive ductal carcinomas of the breast. The first HER-2/neu-targeted approach to reach the clinic was trastuzumab, a humanized...

  • Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer. Clavarezza, Matteo; Venturini, Marco // Oncology;2009 Supplement 1, Vol. 77, p14 

    HER2-positive breast cancer is characterized by high chemosensitivity. Anthracycline-based chemotherapy is recognized as a very effective adjuvant treatment in HER2-positive disease. One of the possible explanations is the co-amplification of TOPO II-alpha and HER2. However, recent data seem to...

  • Adjuvant chemotherapy for breast cancer: side effects and quality of life. Palmer, B.V.; Walsh, G.A.; McKinna, J.A.; Greening, W.P. // British Medical Journal;12/13/1980, Vol. 281 Issue 6255, p1594 

    Examines the adjuvant chemotherapy for breast cancer in Great Britain. Six-month course of five-drug combination of chlorambucil, methotrexate, fluorouracil, vincristine, and adriamycin treatment for post operative chemotherapy; Interference of side effects on the lifestyle of patients and of...

  • Documentation of capecitabine usage as a thirdline chemotherapy option for metastic breast cancer patients. Rajora, Anuparam; Chow, Katherine S.; Vu, Thanh T.; Chambers, Carole R. // Journal of Oncology Pharmacy Practice;Nov2000, Vol. 6 Issue 4, p138 

    Reports on the documentation of capecitabine usage as a third-line chemotherapy option for metastatic breast cancer patients in the period between December 1995 to April 2000. Side effects experienced by patients including hand-foot syndrome, diarrhea and nausea; Side effect-related dose...

  • Paclitaxel.  // Reactions Weekly;2/21/2009, Issue 1240, p34 

    The article presents cases of two elderly women who developed painful skin reactions during treatment with paclitaxel for breast cancer. The first patient developed a skin reaction involving the upper part of her hands and the periocular region, following her fifth cycle of paclitaxel. The...

  • Trastuzumab.  // Reactions Weekly;10/31/2009, Issue 1276, p29 

    The article presents case reports of patients who developed cardiomyopathy during treatment with trastuzumab for breast cancer. All patients, aged 27-56 years and had breast cancer, started receiving trastuzumab with an anthracycline and all of them also previously received radiotherapy. All of...

  • More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review. Badulescu, Florin; Badulescu, Adriana; Paul, Doru; Popescu, Carmen Florina; Florescu, Cristina // OncoTargets & Therapy;2014, Vol. 7, p1911 

    The main concern of long-term use of trastuzumab remains its association with potential cardiac side effects. Although these side effects are real, they are probably overemphasized. We report the case of a woman with metastatic breast cancer, who is currently in complete remission, and who...

  • Chemotherapy in breast cancer.  // British Medical Journal;10/9/1976, Vol. 2 Issue 6040, p832 

    Examines the reaction of the media on the coverage of using adjuvant chemotherapy in breast cancer. Status of adjuvant chemotherapy in early breast cancer; Types of drugs in the treatment of cancer contributing the risk of developing other cancers; Properties of drugs.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics